Scholarlink

<p>Galcanezumab is approved in the EU for migraine prophylaxis in adults; although its efficacy has been demonstrated in multiple phase 3 clinical trials, long-term real-world data remain limited. This Adis Summary of Research summarizes the long-term effectiveness of galcanezumab for migraine prophylaxis based on a retrospective observational cohort study from Italy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adis summary of research: Long-term effectiveness of galcanezumab in the prevention of migraine: an Italian retrospective analysis (REALITY)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Yahiya Y. Syed

摘要

Galcanezumab is approved in the EU for migraine prophylaxis in adults; although its efficacy has been demonstrated in multiple phase 3 clinical trials, long-term real-world data remain limited. This Adis Summary of Research summarizes the long-term effectiveness of galcanezumab for migraine prophylaxis based on a retrospective observational cohort study from Italy.